| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| Company: Precision Biosensors |
| Recipient: You |
|
| Stock and Other Ownership Interests |
| Company: Elicio Therapeutics |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Natera |
| Recipient: You |
| Company: Foundation Medicine |
| Recipient: You |
| Company: MSD Oncology |
| Recipient: You |
| Company: Tempus |
| Recipient: You |
| Company: Bayer |
| Recipient: You |
| Company: Lilly |
| Recipient: You |
| Company: Delcath Systems |
| Recipient: You |
| Company: QED Therapeutics |
| Recipient: You |
| Company: SERVIER |
| Recipient: You |
| Company: Taiho Oncology |
| Recipient: You |
| Company: Exact Sciences |
| Recipient: You |
| Company: Daiichi Sankyo/Astra Zeneca |
| Recipient: You |
| Company: Eisai |
| Recipient: You |
| Company: Seattle Genetics |
| Recipient: You |
| Company: SAGA Diagnostics |
| Recipient: You |
| Company: Illumina |
| Recipient: You |
| Company: BostonGene |
| Recipient: You |
| Company: NeoGenomics Laboratories |
| Recipient: You |
| Company: Elicio Therapeutics |
| Recipient: You |
| Company: BostonGene |
| Recipient: You |
| Company: Guardant Health |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: Taiho Pharmaceutical |
| Recipient: Your Institution |
| Company: Ipsen |
| Recipient: Your Institution |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Advanced Accelerator Applications |
| Recipient: Your Institution |
| Company: Tersera |
| Recipient: Your Institution |
| Company: Boston Scientific |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: AstraZeneca |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|